← All themes Genomics & Gene Editing

Gene Therapy

Gene therapy delivers a working copy of a gene, or a correction to a faulty one, usually once and for life. Manufacturing the delivery vector is often harder than designing the therapy.

131 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
101	101 Passage Bio PASG $12.5M	–	–	–	–
102	102 PharmaCyte Biotech PMCB $3.87M	–	–	–	–
103	103 Prime Medicine PRME $631M	–	–	–	–
104	104 ProKidney PROK $305M	–	–	–	–
105	105 DELISTED Poseida Therapeutics, Inc. Common Stock PSTX	–	–	–	–
106	PTE 106 DELISTED PolarityTE, Inc. Common Stock PTE	–	–	–	–
107	107 uniQure QURE $1.49B	–	–	–	–
108	108 Ultragenyx Pharmaceutical RARE $1.5B	–	–	–	–
109	109 Rocket Pharmaceuticals RCKT $250M	–	–	–	–
110	RCOR 110 DELISTED Renovacor, Inc. RCOR	–	–	–	–
111	111 Regenxbio RGNX $459M	–	–	–	–
112	112 Cartesian Therapeutics RNAC $199M	–	–	–	–
113	RUBY 113 DELISTED Rubius Therapeutics, Inc RUBY	–	–	–	–
114	114 Sana Biotechnology SANA $736M	–	–	–	–
115	SCPS 115 DELISTED Scopus BioPharma Inc. Common Stock SCPS	–	–	–	–
116	SCTX 116 Scribe Therapeutics Inc SCTX $390M	–	–	–	–
117	SGTX 117 DELISTED Sigilon Therapeutics, Inc. Common Stock SGTX	–	–	–	–
118	SIOX 118 DELISTED Sio Gene Therapies Inc. Common Stock SIOX	–	–	–	–
119	SLBT 119 SL Science Holding Ltd SLBT $948M	–	–	–	–
120	120 Solid Biosciences SLDB $599M	–	–	–	–
121	121 Senti Biosciences Holdings SNTI $7.78M	–	–	–	–
122	SQZ 122 DELISTED SQZ Biotechnologies Company SQZ	–	–	–	–
123	TCBP 123 DELISTED TC BioPharm (Holdings) plc American Depositary Shares TCBP	–	–	–	–
124	TCRR 124 DELISTED TCR2 Therapeutics Inc. Common Stock TCRR	–	–	–	–
125	125 TScan Therapeutics TCRX $16M	–	–	–	–